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Abstract. In India, visceral leishmaniasis (VL) caused by Leishmania donovani has been successfully treated with
miltefosine with a cure rate of > 90%. To assess the efﬁcacy and safety of oral miltefosine against Brazilian VL, which is
caused by Leishmania infantum, a phase II, open-label, dose-escalation study of oral miltefosine was conducted in
children (aged 2–12 years) and adolescent-adults (aged 13–60 years). Deﬁnitive cure was assessed at a 6-month follow-
up visit. The cure rate was only 42% (6 of 14 patients) with a recommended treatment of 28 days and 68% (19 of 28
patients) with an extended treatment of 42 days. The in vitro miltefosine susceptibility proﬁle of intracellular amastigote
stages of the pretreatment isolates, from cured and relapsed patients, showed a positive correlation with the clinical
outcome. The IC50mean (SEM) of eventual cureswas 5.1 (0.4) μM,whereas that of eventual failureswas 12.8 (1.9) μM (P=
0.0002). An IC50 above 8.0 μM predicts failure with 82% sensitivity and 100% speciﬁcity. The ﬁnding of L. infantum
amastigotes resistant to miltefosine in isolates from patients who eventually failed treatment strongly suggests natural
resistance to this drug, as miltefosine had never been used in Brazil before this trial was carried out.
INTRODUCTION
American visceral leishmaniasis (VL), causedby Leishmania
infantum (synonymous with Leishmania chagasi in Brazil), is a
major health problem in many parts of Brazil. The disease is
usually fatal if untreated and is characterized clinically by fever,
gradual weight loss, splenomegaly, hypergammaglobulinemia,
and pancytopenia.1
Visceral leishmaniasis treatment has been challenging be-
cause it relies on a few classic agents (pentavalent antimony,
amphotericin B deoxycholate), all of which are parenteral and
poorly tolerated. In Brazil, the standard therapeutic regimen is
20 mg Sbv/kg/day, for a minimum of 20 days. Amphotericin B
deoxycholate is the second-line drug of choice. Lipid formu-
lations of amphotericin B are less toxic but more expensive
and, as a result, only available under request to theMinistry of
Health for patients with severe diseasewith complications, for
example, bleeding, and for children younger than 1 year and
patients older than 50 years.2
In this scenario of scarcity of efﬁcacious drugs, in the late
1990s, an oral drug,miltefosine (hexadecylphosphocholine), a
phospholipid analogue, was considered an important ad-
vance in leishmaniasis therapy. Although developed originally
as an anticancer drug, miltefosine is relatively safe and be-
came the ﬁrst-line therapy in India, where VL is caused by
Leishmaniadonovani. The reportedcured rateswerehighboth
in adults and in children, 94–95%.3,4 However, efﬁcacy de-
creasedafter extensive use in the Indian subcontinent over the
ensuing decade.5–7
There are no data on miltefosine effectiveness against
VL caused by L. infantum in South America. This study was
designed to evaluate the efﬁcacy and safety of miltefosine in a
phase II trial, in Brazilian patients with VL and investigate
whether the clinical outcome could be associated with in vitro
susceptibility of the parasites to miltefosine.
MATERIALS AND METHODS
Study design. This was a phase II, open-label, dose-
escalation study of oral miltefosine (Impavido®, supplied by
AEterna Zentaris) in children (aged 2–12 years) and in
adolescent-adults (aged 13–60 years) at two sites in Brazil,
Montes Claros and Teresina. The objective was to investigate
if efﬁcacy and safety of oral miltefosine in Brazilian VL patients
were similar to that already published for Indian VL patients.
Patients. The patients were enrolled and treated in 2005.
Inclusion criteria were newly diagnosed (untreated) VL, with
parasitological conﬁrmation via visualization of amastigotes
in tissue samples or a positive culture, and either gender.
Exclusion criteria were severe decreases in the formed ele-
ments of the blood or host biochemical abnormalities: platelet
count < 30 × 109/L; white blood count (WBC) < 1 × 109/L;
hemoglobin < 5 g/100 mL; liver enzymes ³ 3 times upper limit
of normal range; serum creatinine or BUN ³ 1.5 times upper
limit of normal range. Other exclusion criteria were evidence of
serious underlying disease (cardiac, renal, hepatic, or pul-
monary); immunodeﬁciency or antibody toHIV; severe protein
and/or caloric malnutrition (Kwashiorkor, Marasmus); any
non-compensated or uncontrolled condition; and lactation,
pregnancy (to be determined by adequate test), or inadequate
contraception in females of childbearing potential for treat-
ment period plus 2 months.
Treatment. The ﬁrst patients were treated at Montes
Claroswith the recommended regimenof 2.5mgmiltefosine/
kg/day, using the 10mg formulation for 28 days. Adolescent-
adults received 100 mg/day (one 50 mg capsule twice a day
withmeals), the same dose used in India.When cure rates for
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the 14 patients at Montes Claros were seen to be low, sub-
sequent patients at Teresina were administered drug at the
same daily dose (2.5 mg/kg/day for children, 100 mg/day for
adults) for 42 days in an attempt to increase cure rates.
Follow-up. Patients were seen in follow-up at the end of
treatment to ascertain initial cure and for 6 months after the
end of therapy to ascertain ﬁnal cure.
Endpoints. Failurewas deﬁned by clinical and parasitological
criteria: signs or symptoms suggestive of leishmaniasis, ac-
companied by conﬁrmation of the presence of Leishmania in a
bone marrow aspirate at that time. Cure was lack of failure. The
primary endpoint was efﬁcacy: the rate of cure by the end of
follow-up 6 months after treatment. Other endpoints were ad-
verse events and correlation of in vitro susceptibility with cure.
Sample size. The sample size was chosen for convenience:
up to 40 pediatric and 40 adolescent-adult patients (Figure 1).
In vitro susceptibility of amastigotes to miltefosine.
Leishmania isolates from both sites were obtained before
treatment bybonemarrowaspiration from26of the ﬁnal total of
40patients. Promastigoteswere grown in liver infusion tryptose
(LIT) medium supplemented with 10% heat-inactivated fetal
calf serum (Hi-FCS). All isolates were previously identiﬁed as
L. infantum using polymerase chain reaction–restriction frag-
ment length polymorphism.8 The miltefosine susceptibility of
intracellular amastigote was performed as follows: adherent
macrophages fromperitoneal ﬂuid of Swissmicewere infected
with late-log phase promastigotes at a ratio of seven parasites
to one macrophage, using the 16-well Lab-Tek tissue culture
slides (Nunc, NY). After 24 hours of incubation in Roswell Park
Memorial Institute (RPMI-1640) supplemented with 10% Hi-
FCS in 5%CO2 at 37C, free promastigoteswere removed and
the culture was then exposed to different concentrations of
miltefosine (0, 0.55, 1.67, 5, and 15 μM) in triplicate. Higher
concentrations were not tested because of drug toxicity to the
infected macrophage. After 72 hours of additional incubation,
the slideswere stainedwithDiff-Quicksolutionsand100cells in
eachwellwerecounted todetermine thepercentageof infected
macrophages. Drug activity was determined from the per-
centage of infected cells in drug-treated cultures relative to
nontreated cultures. The half-maximal inhibitory concentra-
tions (IC50) of miltefosine for amastigotes were calculated from
nonlinear regression analysis, using GraphPad Prism v.7.0a
software (GraphPadSoftware,SanDiego,CA).The resultswere
expressed as the mean of three independent experiments. All
assays were carried out blind regarding isolate identity and
clinical outcome.
Ethical reviewboard. Informedconsentwasobtained from
all study participants and/or guardians before enrollment. The
studyprotocol was reviewed and approved by the Institutional
ReviewBoard of theUniversidadeEstadual deMontesClaros,
Universidade Federal do Piauı´, and by the Brazilian National
Review Board (CONEP D-18506-Z019). ClinicalTrials.gov
Identiﬁer: NCT00378495.
RESULTS
Montes Claros site. Fourteen patients were enrolled in the
clinical trial. Of these, 8 (57%), all children, failed to respond to
treatment. The time of clinical and parasitological failure oc-
curred at 1 month (one patient), 2 months (ﬁve patients), and
5 months (two patients) after the end of treatment (Figure 1).
Laboratory and clinical data of cured and not cured patients
are shown in Table 1. Adverse eventswereminor and included
vomiting (four patients), nausea (three patients), and abdom-
inal pain (two patients). These symptoms resolved when drug
was given with the main meals.
Because of the high failure rates for these ﬁrst 14 patients,
the protocol was amended for subsequent patients such that
FIGURE 1. Flow charts of phase-II Brazilian miltefosine trial. This ﬁgure appears in color at www.ajtmh.org.
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they received the same daily dose but for an extended period
of 42 days. These subsequent patients were enrolled at the
site in Teresina.
Teresina site. Thirty patients were enrolled. Four patients
prematurely terminated treatment: one patient because HIV
infection was detected and three patients because of drug
toxicity. A 56-year-old male was removed on day 12 because
of renal toxicity and suspected treatment failure; a 4-year-old
femalewas removed on day 6 because of vomiting; a 26-year-
old male was removed on day 12 because of liver toxicity and
suspected treatment failure. Thus, 26patients (12children and
14 adolescent-adults) completed the 42 days of treatment of
whom 7 (three children and four adolescent-adults) failed to
respond to treatment. The time of clinical and parasitological
failure was at 1 month (one patient), 3 months (three patients),
4 months (two patients), and 6 months (one patient) after the
end of treatment. Considering all 28 evaluable patients (26 per
protocol patients plus two patients who may have failed at
the time they were removed for reasons of intolerance), there
were nine failures (32%) consisting of three children and six
adolescent-adults. If we use an intention-to-treat analysis,
considering all 30 enrolled patients, there were 11 failures
(36%). Laboratory and clinical data of cured and not cured
patients are shown in Table 1 and Figure 1.
Both sites. A summary of the outcomes for all patients
enrolled at both clinical sites is shown in Table 2. For children,
extension of treatment period from 28 days (Montes Claros
site) to 42 days (Teresina site) improved the cure rate from
43%to67%, althoughwith the small number of patients in this
phase II study, this difference was not statistically signiﬁcant
(P = 0.0995: Fischer’s exact test). For adolescent-adults, the
cure rate at the Teresina site, the only site with appreciable
numbers of patients, was 69%. Inspection of the entrance
characteristics does not reveal obvious differences between
parameter values for patients destined to cure or to fail treat-
ment with miltefosine (Table 1).
Miltefosine susceptibility of L. infantum isolates. To test
if the differences in clinical outcome to miltefosine treatment
could be explained by variance in miltefosine susceptibility of
the infecting parasite L. infantum, the in vitro susceptibility
of intracellular amastigote of L. infantum to miltefosine was
assessed for pretreatment parasites from 26 patients: 14
parasite isolates came from patients who cured and 12 par-
asite isolates from patients who failed. There was no signiﬁ-
cant difference in L. infantum infectivity on a peritoneal mouse
macrophage model when pretreatment isolates from cured
patients and those who failed were compared (Figure 2A).
Moreover, no differences were observed in L. infantum
infectivity ratio between parasites containing or not the
miltefosine sensitivity locus (MSL), which we previously as-
sociated with miltefosine treatment outcomes9 (Figure 2B).
Miltefosine concentration that reduces 50% of infected
macrophages (IC50) was calculated and the in vitro IC50 values
of these pretreatment isolates showed a signiﬁcant difference
between isolates from patients who were cured (mean IC50 =
5.1 μM: SEM = 0.4 μM) and those who failed (mean IC50 =
12.8 μM: SEM = 1.9 μM): P = 0.0002 via t-test (Figure 2C). The
in vitro susceptibility assay also showed a signiﬁcant differ-
ence between isolates MSL+ (mean IC50 = 5.9 μM: SEM =
1.0μM)andMSL− (mean IC50=10.9μM:SEM=1.8μM),which
corroborates our previous association between MSL and
treatment outcome (Figure 2D). By ROC curve analysis, the
IC50 of 8.0 μMwas highlighted as the best discrimination point
TABLE 1
Entrance and end-of-treatment data
Site 1: Montes Claros 2: Teresina
Treatment duration 28 days 42 days
Parameter Day 0* Day 28* Day 0* Day 42*
Age (years)
Cured 17 (2–43) NA 19 (2–53) NA
Failed 5 (2–11) NA 17 (2–41) NA
Duration of illness (days)
Cured 28 (5–60) NA 38 (9–60) NA
Failed 32 (15–90) NA 50 (21–120) NA
Spleen size (cm)
Cured 8.3 (4–15) 2.8 (0–4.5) 8.8 (2–14.5) 1.8 (0–5.5)
Failed 10.5 (7–12.5) 4.1 (2–4.5) 8.5 (0–12) 3.1 (0–7)
Hemoglobin (g/dL)
Cured 8.8 (6.6–12) 11.6 (10–13.7) 8.5 (5.2–10.8) 11.5 (7.5–14.6)
Failed 8.3 (6.7–10.6) 10.0 (8.7–12.3) 8.4 (6–11) 11.3 (10.2–13.5)
WBC (×1,000/mm3)
Cured 3.6 (1.8–7.3) 6.8 (2.7–14.4) 3.2 (1.3–8.9) 7.8 (2.4–15.2)
Failed 3.5 (2.7–5.3) 7.7 (6.1–12.9) 2.6 (1.6–3.6) 7.5 (3.6–11.8)
Albumin (g/dL)
Cured 3.1 (2.6–3.9) 4.3 (3.7–4.9) 3.3 (2.6–3.9) 4.0 (3.5–4.8)
Failed 3.6 (3–4) 4.2 (3.9–4.9) 3.3 (2.4–4.3) 4.1 (3.6–4.8)
* Data represent mean (range) of values.
Laboratory reference values: hemoglobin, 12–17 g/dL; WBC, 5,000–10,000/mm3; albumin, 3.5–5.5 g/dL.
TABLE 2
Final efﬁcacy data
Children Adolescent-adults All ages
Montes Claros* 11 3 14
Cure 3 (27%) 3 (100%) 6
Failure 8 (73%) 0 (0%) 8
% Cure (95% CI) 27% 100% 43% (18–71)
Teresina† 12 16 28
Cure 8 (67%) 11 (69%) 19
Failure 4 (33%) 3 (19%) 7
Probable failure 0 (0%) 2 (12%) 2
% Cure (95% CI) 67% 69% 68% (48–84)
* Patients from Montes Claros were treated for 28 days.
† Patients from Teresina were treated for 42 days.
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to predict treatment outcome, such that isolates with lower
IC50 would be predicted to cure and higher IC50 would be
predicted to fail. Based on the IC50 values of the 26 L. infantum
isolates, cure was predicted for 17 patients, but only 14 pa-
tients were cured. Among nine isolates for which failure was
predicted, all patients relapsed, resulting in a sensitivity of
82% and speciﬁcity of 100%.
DISCUSSION
The efﬁcacy of miltefosine in the treatment of South Amer-
ican (Brazilian) VL was lower than expected. At the ﬁrst site,
where most patients were pediatric, miltefosine was admin-
istered for the standard 28 days, resulting in a cure rate of
43% (6 of 14 patients). Previous pharmacokinetic studies
showed that miltefosine exposure was lower in pediatric pa-
tients compared with adult patients with VL, which has been
linked with treatment failure.10–12 However, a comparable
pediatric and adolescent-adult cure rate (67% and 69%, re-
spectively) was observed at the second site, where an
extended period of treatment (42 days) was performed. In a
nonrandomized comparison, the extended treatment course
improved slightly the cure rate compared with the 28-day stan-
dard regimen (68% or 64% in an intention to treat analysis).
Nevertheless, this cure rate is far below the > 90% cure rate for
miltefosine reported in Indian VL before its widespread use.2–4,13
Because the values of entrance clinical and laboratory pa-
rameters did not predict eventual cure and confounding
concomitant diseases were ruled out by exclusion criteria, we
hypothesized that inherent differences in parasite suscepti-
bility to drug might be predictive of therapeutic success. To
this end, we cultured parasites from 26 of the 40 enrolled
patients, with approximately equal numbers of parasites from
eventual cures (14 parasites) and failures (12 parasites). The
in vitro miltefosine susceptibility phenotype of intracellular
amastigotes showed that IC50 values of the pretreatment
isolates were able to distinguish eventual cures from eventual
failures, strongly suggesting that treatment failure observed
in Brazil is associated with natural resistance of L. infantum
parasite to miltefosine.
FIGURE 2. Infectivity and in vitro miltefosine susceptibility of L. infantum isolates collected before treatment for cured and failed patients. (A) and
(B) Infection ratio, percentage of infectedmacrophage 96 hours post infectionwith L. infantum isolates. (C) and (D) In vitromiltefosine susceptibility
of intracellular amastigote stage of L. infantum isolates. Each symbol represents the value for an individual L. infantum isolate. The horizontal bars
in panels indicate the mean values for the groups and the standard errors of the means. Asterisk indicates signiﬁcant difference between groups
(t-test). MSL− = homogeneous population for absence of MSL; MSL+ = homogeneous/heterogeneous population for presence of MSL.
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Killing of parasites by drugs depends on pharmacokinetics
and pharmacodynamics, which may vary in different VL pa-
tients in different parts of the world. For Indian subcontinent
VL, the lower rate of efﬁcacy of miltefosine in children versus
adolescent-adults14 may be linked to lower exposure of the
drug in children.15 With respect to activity of drug against the
parasite, Prajapati et al.16 found similar pretreatment IC50 in
promastigotes from patients destined to cure (5.8 μM) com-
pared with patients destined to fail (4.5 μM). However, there
was a slight increase in parasite resistance to miltefosine as
shown by an increase in IC50 posttreatment (6.1 μM) com-
pared with pretreatment (3.7 μM). Bhandari et al.17 showed an
increase in IC50 in isolates at the time of failure (4.7 μM)
compared with pretreatment (1.9 μM), and Deep et al.18 con-
ﬁrmed that IC50 increase on failure (11 μM) compared with
pretreatment (3.9 μM). Our present report appears unique in
ﬁnding signiﬁcant differences between the activity of milte-
fosine against VL pretreatment that correlate with eventual
treatment outcome. Our ﬁndings are of particular interest
because, as mentioned previously, the different susceptibility
of Leishmania to miltefosine that correlates with clinical out-
come is inherent to Brazilian L. infantum because these data
from 2005 predates any use of this drug in Brazil.
Our recent genomic analysis showed a strong association
(P = 0.0005) between the deletion of the L. infantumMSL and
miltefosine treatment failure. The absence of MSL in the par-
asite increases the risk of treatment failure 9.4-fold and pre-
dicts miltefosine failure with 92% sensitivity and 78%
speciﬁcity, which highlights MSL as a potential molecular
marker to predict miltefosine treatment outcome in VL.9 Our
data suggest that neither the presence nor absence of the
MSL inﬂuences the ability of the parasites to infect macro-
phages in vitro. However, there is a strong correlation be-
tween thepresenceof theMSLand the in vitro susceptibility of
amastigote stage to miltefosine (P = 0.0301). This result
highlights that screening for the presence of the MSL by po-
lymerase chain reaction could be a convenient prognostic
marker in clinical practice to predict efﬁcacy of miltefosine
because it can be performed directly on biological samples in
a much shorter time than the in vitro characterization of the
susceptibility of the parasite to miltefosine. The molecular
mechanism involved in the resistance of L. infantum to milte-
fosine in these strains, however, is still unknownandsubject to
further investigation.
Finally, some limitations of our study should be taken into
account: (1) the lack of a randomized controlled trial can limit
inferences from our results; (2) this trial was carried out at only
two sites, one in the northeast and the other in the southeast
part ofBrazil; (3) the trial had tobe interruptedbefore it reached
the planned simple size, because of ethical reasons (low efﬁ-
cacy), resulting in only 44 patients enrolled; (4) the trial was
split into two different dosing regimens. Moreover, consider-
ing that the L. infantum studied here were isolated over a de-
cade ago, it is also important to know themiltefosine-resistant
phenotype throughout Brazil now.Wehave started to address
this point by screening for theMSL frequency in different areas
of Brazil and found that MSL frequency changes geo-
graphically (data not shown), indicating that miltefosine could
be successfully used after MSL stratiﬁcation in some parts of
Brazil.9
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